AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca PLC of UK.
This information can be found in the financial results section.
In 2007 we invested $5.2 billion on R&D.
We employ over 67,000 people worldwide.
- 17% in the United Kingdom
- 38% in Continental Europe
- 30% in the Americas
- 15% in Asia, Africa and Australasia
The 2008 Annual General Meeting will be held on Thursday, 24 April 2008 in London.
The 2007 Annual General Meeting was held on Thursday, 26 April 2007 in London with a satellite link to Sweden. View the results of voting.
Second quarter and six months results will be announced on Thursday 31 July 2008. Read more information about this event.
AstraZeneca is traded on the London, New York and Stockholm Stock Exchanges. The symbol is AZN in all three markets. View interactive charts for the London, New York and Stockholm stock exchanges .
What is AstraZeneca's current debt rating?
Moody's:
Long term: A1, Short term: P-1, Outlook: Stable
Standard & Poor's:
Long term AA-, Short term A-1+, Outlook: Stable
Fitch:
Long term AA-, Short term F1+, Outlook: Stable
046353108
As at 31 March 2008 there were 1,457 million shares in issue.
AstraZeneca adheres to the International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) with appropriate conversion to US GAAP being shown in our financial statements.
AstraZeneca reports in US dollars.
|